MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

Acta Neuropathologica

Volumn 123, Issue 4, 2012, Pages 501-513

  Ryan, Sarra L ^a   Schwalbe, Ed C ^a   Cole, Michael ^a   Lu, Yuan ^a   Lusher, Meryl E ^a   Megahed, Hisham ^a   O'Toole, Kieran ^a   Nicholson, Sarah Leigh ^a   Bognar, Laszlo ^b   Garami, Miklos ^c   Hauser, Peter ^c   Korshunov, Andrey ^d   Pfister, Stefan M ^d   Williamson, Daniel ^a   Taylor, Roger E ^e   Ellison, David W ^f   Bailey, Simon ^a   Clifford, Steven C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e SINGLETON HOSPITAL   (United Kingdom)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Biomarkers; Medulloblastoma; MYC; MYCN; Prognosis

Indexed keywords

ADOLESCENT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER PROGNOSIS; CHILD; CHILDHOOD CANCER; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METASTASIS; ONCOGENE MYC; ONCOGENE MYCC; ONCOGENE MYCL; ONCOGENE MYCN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SURVIVAL PREDICTION; SURVIVAL RATE;

ADOLESCENT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEDULLOBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MYC; RISK FACTORS; RNA, MESSENGER; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84862685324     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-011-0923-y     Document Type: Article

References (28)

1. Adhikary S, Eilers M (2005) Transcriptional regulation and transformation by Myc proteins. Natl Rev Mol Cell Biol 6:635-645 (Pubitemid 41081267)
2. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126:540-544 (Pubitemid 34477948)
3. Chang CH, Housepian EM, Herbert C Jr. (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93:1351-1359
4. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424-1430
5. Curran EK, Sainani KL, Le GM, Propp JM, Fisher PG (2009) Gender affects survival for medulloblastoma only in older children and adults: a study from the Surveillance Epidemiology and End Results Registry. Pediatr Blood Cancer 52:60-64
6. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381-396
7. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400-1407
8. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ (2004) Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22: 984-993 (Pubitemid 41095029)
9. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, Sutton LN, Rorke LB, Brodeur GM, Phillips PC (2001) MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433 (Pubitemid 32751645)
10. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512 (Pubitemid 28425575)
11. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA (2000) C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89:395-402
12. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification oftumors of the nervous system. J Neuropathol Exp Neurol 61:215-225 (discussion 226-9) (Pubitemid 34212595)
13. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3:e3088
14. Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schottler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister SM (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28:3054-3060
15. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493 (Pubitemid 39100486)
16. Langdon JA, Lamont JM, Scott DK, Dyer S, Prebble E, Bown N, Grundy RG, Ellison DW, Clifford SC (2006) Combined genomewide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer 45:47-60 (Pubitemid 46930861)
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109 (Pubitemid 47103521)
18. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD (2009) The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69:3249-3255
19. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414
20. Pelengaris S, Khan M, Evan G (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2:764-776 (Pubitemid 37328911)
21. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27:1627-1636
22. Pizer BL, Clifford SC (2009) The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 23:364-375
23. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13:2651-2657 (Pubitemid 46788032)
24. Salsano E, Croci L, Maderna E, Lupo L, Pollo B, Giordana MT, Consalez GG, Finocchiaro G (2007) Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro Oncol 9:298-307 (Pubitemid 47169662)
25. Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC (2011) Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 17:1883-1894
26. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L (2010) Pleiotropic role for MYCN in medulloblastoma. Genes Dev 24:1059-1072
27. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591 (Pubitemid 46594113)
28. Zitterbart K, Filkova H, Tomasikova L, Necesalova E, Zambo I, Kantorova D, Slamova I, Vranova V, Zezulkova D, Pesakova M, Pavelka Z, Veselska R, Kuglik P, Sterba J (2011) Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol 102:25-33